Regeneron Pharmaceuticals Investor Presentation — June 2020

Document content

This presentation includes forward -looking statements thatinvolve risks anduncertainties relating tofuture events andthefuture performance ofRegeneron Pharmaceuticals, Inc.(“Regeneron” orthe“Company”), andactual

events orresults may differ materially from these forward -looking statements .Words such as“anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations ofsuch words, andsimilar expressions areintended

toidentify such forward -looking statements, although notallforward -looking statements contain these identifying words .These statements concern, andthese risks anduncertainties include, among others, theimpact of

SARS -CoV-2(thevirus thathascaused theCOVID -19pandemic) onRegeneron's business anditsemployees, collaborators, suppliers, andother third parties onwhich Regeneron relies, Regeneron's anditscollaborators’

ability tocontinue toconduct research and clinical programs, Regeneron's ability tomanage itssupply chain, netproduct sales ofproducts marketed byRegeneron and/or itscollaborators (collectively, "Regeneron’s

Products"), andtheglobal economy ;thenature, timing, andpossible success andtherapeutic applications ofRegeneron’s Products andRegeneron’s product candidates andresearch andclinical programs now underway or

planned, including without limitation EYLEA®(aflibercept) Injection, Dupixent®(dupilumab), Libtayo®(cemiplimab), Praluent®(alirocumab), Kevzara®(sarilumab), fasinumab, evinacumab, garetosmab ,pozelimab ,Regeneron’s

oncology programs (including itscostimulatory bispecific portfolio andother therapeutic approaches discussed inthispresentation), Regeneron’s COVID -19antibody program andother earlier -stage product candidates, and

theuseofhuman genetics inRegeneron’s research programs ;theextent towhich theresults from theresearch anddevelopment programs orpreclinical testing conducted byRegeneron oritscollaborators (including the

research anddevelopment programs andpreclinical testing discussed inthispresentation) may bereplicated inother studies andmay lead toadvancement ofproduct candidates toclinical trials ortherapeutic applications ;

unforeseen safety issues resulting from theadministration ofRegeneron’s Products andproduct candidates inpatients, including serious complications orside effects inconnection with theuseofRegeneron’s product

candidates inclinical trials ;thelikelihood andtiming ofpossible regulatory approval andcommercial launch ofRegeneron’s late-stage product candidates andnew indications forRegeneron’s Products, including without

limitation EYLEA, Dupixent, Libtayo, Praluent, Kevzara, fasinumab, evinacumab, REGN -EB3,garetosmab ,pozelimab ,andREGN 1979 ;thelikelihood andtiming ofachieving anyoftheanticipated milestones described inthis